{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:02:59Z","timestamp":1772758979423,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10072-024-07402-1","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T22:02:30Z","timestamp":1708380150000},"page":"3061-3068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging imaging markers in radiologically isolated syndrome: implications for earlier treatment initiation"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4212-906X","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Moura","sequence":"first","affiliation":[]},{"given":"Cristina","family":"Granziera","sequence":"additional","affiliation":[]},{"given":"Monica","family":"Marta","sequence":"additional","affiliation":[]},{"given":"Ana Martins","family":"Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"7402_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S et al (2016) Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 9:S5\u2013S48","journal-title":"Mult Scler Relat Disord"},{"key":"7402_CR2","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato PM, Centonze D et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269:5382\u20135394","journal-title":"J Neurol"},{"key":"7402_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","volume":"72","author":"TD Okuda","year":"2009","unstructured":"Okuda TD, Mowry ME, Beheshtian A et al (2009) Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome. Neurology 72:800\u2013805","journal-title":"Neurology"},{"key":"7402_CR4","doi-asserted-by":"publisher","first-page":"e19452","DOI":"10.1371\/journal.pone.0019452","volume":"6","author":"DN Stefano","year":"2011","unstructured":"Stefano DN, Stromillo LM, Rossi F et al (2011) Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. PLoS ONE 6:e19452","journal-title":"PLoS ONE"},{"key":"7402_CR5","doi-asserted-by":"publisher","first-page":"e90509","DOI":"10.1371\/journal.pone.0090509","volume":"9","author":"TD Okuda","year":"2014","unstructured":"Okuda TD, Siva A, Kantarci O et al (2014) Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE 9:e90509","journal-title":"PLoS ONE"},{"key":"7402_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ana.25799","volume":"88","author":"C Lebrun-Frenay","year":"2020","unstructured":"Lebrun-Frenay C, Kantarci O, Siva A, Sormani PM, Pelletier D, Okuda TD (2020) Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. Ann Neurol 88:407\u2013417","journal-title":"Ann Neurol"},{"key":"7402_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"JA Thompson","year":"2018","unstructured":"Thompson JA, Banwell LB, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology 17:162\u2013173","journal-title":"The Lancet Neurology"},{"key":"7402_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/1352458517717808","volume":"24","author":"DN Stefano","year":"2018","unstructured":"Stefano DN, Giorgio A, Tintor\u00e9 M et al (2018) Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Mult Scler J 24:214\u2013221","journal-title":"Mult Scler J"},{"key":"7402_CR9","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1093\/brain\/awad073","volume":"146","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay C, Okuda TD, Siva A et al (2023) The radiologically isolated syndrome: revised diagnostic criteria. Brain 146:3431\u20133443","journal-title":"Brain"},{"key":"7402_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein D, Montalban X (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15:287\u2013300","journal-title":"Nat Rev Neurol"},{"key":"7402_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14737175.2023.2208347","volume":"23","author":"A Morgan","year":"2023","unstructured":"Morgan A, Tallantyre E, Ontaneda D (2023) The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother 23:433\u2013444","journal-title":"Expert Rev Neurother"},{"key":"7402_CR12","doi-asserted-by":"crossref","unstructured":"Smith C, Khanna R (2023) Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis. Clin Transl Immunol 12(3):e1444","DOI":"10.1002\/cti2.1444"},{"key":"7402_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner JT, Wiendl H (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol 19:289\u2013304","journal-title":"Nat Rev Neurol"},{"key":"7402_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41582-022-00675-0","volume":"18","author":"J Oh","year":"2022","unstructured":"Oh J, Bar-Or A (2022) Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nat Rev Neurol 18:466\u2013475","journal-title":"Nat Rev Neurol"},{"key":"7402_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s00415-022-11488-y","volume":"270","author":"M Filippi","year":"2023","unstructured":"Filippi M, Preziosa P, Arnold LD et al (2023) Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective. J Neurol 270:1286\u20131299","journal-title":"J Neurol"},{"key":"7402_CR16","doi-asserted-by":"crossref","unstructured":"Gill AJ, Schorr EM, Gadani SP, Calabresi PA (2023) Emerging imaging and liquid biomarkers in multiple sclerosis. Eur J Immunol 53(8):e2250228","DOI":"10.1002\/eji.202250228"},{"key":"7402_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1177\/13524585221118677","volume":"28","author":"I Meaton","year":"2022","unstructured":"Meaton I, Altokhis A, Allen MC et al (2022) Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. Mult Scler J 28:2212\u20132220","journal-title":"Mult Scler J"},{"key":"7402_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/RLI.0000000000000804","volume":"56","author":"VB Ineichen","year":"2021","unstructured":"Ineichen VB, Beck SE, Piccirelli M, Reich SD (2021) New prospects for ultra-high-field magnetic resonance imaging in multiple sclerosis. Invest Radiol 56:773\u2013784","journal-title":"Invest Radiol"},{"key":"7402_CR19","doi-asserted-by":"publisher","first-page":"175628641985972","DOI":"10.1177\/1756286419859722","volume":"12","author":"R Cortese","year":"2019","unstructured":"Cortese R, Collorone S, Ciccarelli O, Toosy TA (2019) Advances in brain imaging in multiple sclerosis. Ther Adv Neurol Disord 12:175628641985972","journal-title":"Ther Adv Neurol Disord"},{"key":"7402_CR20","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1212\/WNL.0b013e3181ff96f6","volume":"75","author":"M Filippi","year":"2010","unstructured":"Filippi M, Rocca AM, Calabrese M et al (2010) Intracortical lesions: Relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 75:1988\u20131994","journal-title":"Neurology"},{"key":"7402_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/ane.13553","volume":"145","author":"L Chaaban","year":"2022","unstructured":"Chaaban L, Safwan N, Moussa H, El-Sammak S, Khoury JS, Hannoun S (2022) Central vein sign: A putative diagnostic marker for multiple sclerosis. Acta Neurol Scand 145:279\u2013287","journal-title":"Acta Neurol Scand"},{"key":"7402_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ana.25146","volume":"83","author":"P Maggi","year":"2018","unstructured":"Maggi P, Absinta M, Grammatico M et al (2018) Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol 83:283\u2013294","journal-title":"Ann Neurol"},{"key":"7402_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14737175.2022.2143265","volume":"22","author":"SM Martire","year":"2022","unstructured":"Martire SM, Moiola L, Rocca AM, Filippi M, Absinta M (2022) What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis? Expert Rev Neurother 22:829\u2013837","journal-title":"Expert Rev Neurother"},{"key":"7402_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1148\/radiology.182.3.1535892","volume":"182","author":"M Brant-Zawadzki","year":"1992","unstructured":"Brant-Zawadzki M, Gillan DG, Nitz RW (1992) MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence\u2013initial experience in the brain. Radiology 182:769\u2013775","journal-title":"Radiology"},{"key":"7402_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrneurol.2010.93","volume":"6","author":"M Calabrese","year":"2010","unstructured":"Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438\u2013444","journal-title":"Nat Rev Neurol"},{"key":"7402_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/1352458509106510","volume":"15","author":"M Calabrese","year":"2009","unstructured":"Calabrese M, Gallo P (2009) Magnetic resonance evidence of cortical onset of multiple sclerosis. Mult Scler J 15:933\u2013941","journal-title":"Mult Scler J"},{"key":"7402_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/jnnp-2017-315863","volume":"89","author":"P Preziosa","year":"2018","unstructured":"Preziosa P, Rocca AM, Mesaros S et al (2018) Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. J Neurol Neurosurg Psychiatry 89:316\u2013318","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7402_CR28","doi-asserted-by":"crossref","unstructured":"Cagol A, Cortese R, Barakovic M, Schaedelin S, Ruberte E, Absinta M, Barkhof F, Calabrese M, Castellaro M, Ciccarelli O, Cocozza S, De Stefano N, Enzinger C, Filippi M, Jurynczyk M, Maggi P, Mahmoudi N, Messina S, Montalban X, Palace J, Pontillo G, Pr\u00f6bstel AK, Rocca MA, Ropele S, Rovira \u00c0, Schoonheim MM, Sowa P, Strijbis E, Wattjes MP, Sormani MP, Kappos L, Granziera C, MAGNIMS study group (2024) diagnostic performance of cortical lesions and the central vein sign in multiple sclerosis. JAMA Neurol 81(2):143\u2013153","DOI":"10.1001\/jamaneurol.2023.4737"},{"key":"7402_CR29","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1212\/WNL.0b013e318238ee9b","volume":"77","author":"A Giorgio","year":"2011","unstructured":"Giorgio A, Stromillo LM, Rossi F et al (2011) Cortical lesions in radiologically isolated syndrome. Neurology 77:1896\u20131899","journal-title":"Neurology"},{"key":"7402_CR30","doi-asserted-by":"publisher","first-page":"103183","DOI":"10.1016\/j.msard.2021.103183","volume":"55","author":"CI George","year":"2021","unstructured":"George CI, Rice RD, Chibnik BL, Mateen JF (2021) Radiologically isolated syndrome: A single-center, retrospective cohort study. Multiple Sclerosis and Related Disorders 55:103183","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"7402_CR31","doi-asserted-by":"publisher","first-page":"e3208","DOI":"10.1097\/MD.0000000000003208","volume":"95","author":"A Labiano-Fontcuberta","year":"2016","unstructured":"Labiano-Fontcuberta A, Mato-Abad V, \u00c1lvarez-Linera J et al (2016) Gray Matter Involvement in Radiologically Isolated Syndrome. Medicine 95:e3208","journal-title":"Medicine"},{"key":"7402_CR32","doi-asserted-by":"publisher","first-page":"e4101","DOI":"10.1097\/MD.0000000000004101","volume":"95","author":"A Labiano-Fontcuberta","year":"2016","unstructured":"Labiano-Fontcuberta A, Mato-Abad V, \u00c1lvarez-Linera J et al (2016) Normal-appearing brain tissue analysis in radiologically isolated syndrome using 3 T MRI. Medicine 95:e4101","journal-title":"Medicine"},{"key":"7402_CR33","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1212\/NXI.0000000000000102","volume":"2","author":"JC Azevedo","year":"2015","unstructured":"Azevedo JC, Overton E, Khadka S et al (2015) Early CNS neurodegeneration in radiologically isolated syndrome. Neurology - Neuroimmunology Neuroinflammation 2:e102","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"key":"7402_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1148\/radiol.2021203071","volume":"299","author":"S Haller","year":"2021","unstructured":"Haller S, Haacke ME, Thurnher MM, Barkhof F (2021) Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. Radiology 299:3\u201326","journal-title":"Radiology"},{"key":"7402_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrneurol.2016.166","volume":"12","author":"P Sati","year":"2016","unstructured":"Sati P, Oh J, Constable TR et al (2016) The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 12:714\u2013722","journal-title":"Nat Rev Neurol"},{"key":"7402_CR36","doi-asserted-by":"publisher","first-page":"120189","DOI":"10.1016\/j.neuroimage.2023.120189","volume":"276","author":"E Biondetti","year":"2023","unstructured":"Biondetti E, Cho J, Lee H (2023) Cerebral oxygen metabolism from MRI susceptibility. Neuroimage 276:120189","journal-title":"Neuroimage"},{"key":"7402_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1212\/WNL.0b013e31820b7630","volume":"76","author":"CE Tallantyre","year":"2011","unstructured":"Tallantyre CE, Dixon EJ, Donaldson I et al (2011) Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology 76:534\u2013539","journal-title":"Neurology"},{"key":"7402_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1352458519876031","volume":"26","author":"P Maggi","year":"2020","unstructured":"Maggi P, Absinta M, Sati P et al (2020) The \u201ccentral vein sign\u201d in patients with diagnostic \u201cred flags\u201d for multiple sclerosis: A prospective multicenter 3T study. Mult Scler J 26:421\u2013432","journal-title":"Mult Scler J"},{"key":"7402_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1352458519882282","volume":"26","author":"AM Clarke","year":"2020","unstructured":"Clarke AM, Samaraweera PA, Falah Y et al (2020) Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty. Mult Scler J 26:433\u2013441","journal-title":"Mult Scler J"},{"key":"7402_CR40","doi-asserted-by":"publisher","first-page":"479.e479","DOI":"10.1016\/j.crad.2020.01.011","volume":"75","author":"A Bhandari","year":"2020","unstructured":"Bhandari A, Xiang H, Lechner-Scott J, Agzarian M (2020) Central vein sign for multiple sclerosis: A systematic review and meta-analysis. Clin Radiol 75:479.e479-479.e415","journal-title":"Clin Radiol"},{"key":"7402_CR41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/diagnostics10121025","volume":"10","author":"M Castellaro","year":"2020","unstructured":"Castellaro M, Tamanti A, Pisani IA, Pizzini BF, Crescenzo F, Calabrese M (2020) The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis. Diagnostics 10:1025","journal-title":"Diagnostics"},{"key":"7402_CR42","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaneurol.2019.2478","volume":"76","author":"T Sinnecker","year":"2019","unstructured":"Sinnecker T, Clarke AM, Meier D et al (2019) Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol 76:1446","journal-title":"JAMA Neurol"},{"key":"7402_CR43","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3174\/ajnr.A6045","volume":"40","author":"S Suthiphosuwan","year":"2019","unstructured":"Suthiphosuwan S, Sati P, Guenette M et al (2019) The Central Vein Sign in Radiologically Isolated Syndrome. Am J Neuroradiol 40:776\u2013783","journal-title":"Am J Neuroradiol"},{"key":"7402_CR44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/WNL.0b013e31820d8b1d","volume":"76","author":"TD Okuda","year":"2011","unstructured":"Okuda TD, Mowry ME, Cree CAB et al (2011) Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 76:686\u2013692","journal-title":"Neurology"},{"key":"7402_CR45","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1177\/13524585211002097","volume":"27","author":"J Oh","year":"2021","unstructured":"Oh J, Suthiphosuwan S, Sati P et al (2021) Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. Mult Scler J 27:2199\u20132208","journal-title":"Mult Scler J"},{"key":"7402_CR46","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.nicl.2022.103194","volume":"36","author":"H Kolb","year":"2022","unstructured":"Kolb H, Al-Louzi O, Beck SE, Sati P, Absinta M, Reich SD (2022) From pathology to MRI and back: Clinically relevant biomarkers of multiple sclerosis lesions. Neuroimage Clin 36:103194","journal-title":"Neuroimage Clin"},{"key":"7402_CR47","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1177\/13524585231162262","volume":"29","author":"C Elliott","year":"2023","unstructured":"Elliott C, Rudko AD, Arnold LD et al (2023) Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler J 29:680\u2013690","journal-title":"Mult Scler J"},{"key":"7402_CR48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"MJ Frischer","year":"2015","unstructured":"Frischer MJ, Weigand DS, Guo Y et al (2015) Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78:710\u2013721","journal-title":"Ann Neurol"},{"key":"7402_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/brain\/awy296","volume":"142","author":"WU Kaunzner","year":"2019","unstructured":"Kaunzner WU, Kang Y, Zhang S et al (2019) Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain 142:133\u2013145","journal-title":"Brain"},{"key":"7402_CR50","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/1352458520958589","volume":"28","author":"A Calvi","year":"2022","unstructured":"Calvi A, Haider L, Prados F, Tur C, Chard D, Barkhof F (2022) In vivo imaging of chronic active lesions in multiple sclerosis. Mult Scler J 28:683\u2013690","journal-title":"Mult Scler J"},{"key":"7402_CR51","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00234-021-02800-0","volume":"64","author":"C Pinto","year":"2022","unstructured":"Pinto C, Cambron M, Dobai A, Vanheule E, Casselman WJ (2022) Smoldering lesions in MS: if you like it then you should put a rim on it. Neuroradiology 64:703\u2013714","journal-title":"Neuroradiology"},{"key":"7402_CR52","doi-asserted-by":"publisher","first-page":"e0256845","DOI":"10.1371\/journal.pone.0256845","volume":"16","author":"KNCK Kwong","year":"2021","unstructured":"Kwong KNCK, Mollison D, Meijboom R et al (2021) The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis. PLoS ONE 16:e0256845","journal-title":"PLoS ONE"},{"key":"7402_CR53","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ana.25877","volume":"88","author":"P Maggi","year":"2020","unstructured":"Maggi P, Sati P, Nair G et al (2020) Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Ann Neurol 88:1034\u20131042","journal-title":"Ann Neurol"},{"key":"7402_CR54","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00330-013-3080-y","volume":"24","author":"DI Kilsdonk","year":"2014","unstructured":"Kilsdonk DI, Wattjes PM, Lopez-Soriano A et al (2014) Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. Eur Radiol 24:841\u2013849","journal-title":"Eur Radiol"},{"key":"7402_CR55","doi-asserted-by":"crossref","unstructured":"Hosseini Z, Matusinec J, Rudko DA, Liu J, Kwan BYM, Salehi F, Sharma M, Kremenchutzky M, Menon RS, Drangova M (2018) Morphology-specific discrimination between MS white matter lesions and benign white matter hyperintensities using ultra-high-field MRI. AJNR Am J Neuroradiol 39(8):1473\u20131479","DOI":"10.3174\/ajnr.A5705"},{"key":"7402_CR56","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3174\/ajnr.A6547","volume":"41","author":"MA Clarke","year":"2020","unstructured":"Clarke MA, Pareto D, Pessini-Ferreira L et al (2020) Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. Am J Neuroradiol 41:1001\u20131008","journal-title":"Am J Neuroradiol"},{"key":"7402_CR57","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/jamaneurol.2020.0124","volume":"77","author":"S Suthiphosuwan","year":"2020","unstructured":"Suthiphosuwan S, Sati P, Absinta M et al (2020) Paramagnetic Rim Sign in Radiologically Isolated Syndrome. JAMA Neurol 77:653","journal-title":"JAMA Neurol"},{"issue":"8","key":"7402_CR58","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/1352458512471874","volume":"19","author":"S Liu","year":"2013","unstructured":"Liu S, Kullnat J, Bourdette D, Simon J, Kraemer DF, Murchison C, Hamilton BE (2013) Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients. Mult Scler 19(8):1101\u20131105","journal-title":"Mult Scler"},{"key":"7402_CR59","doi-asserted-by":"crossref","unstructured":"Rival M, Galoppin M, Thouvenot E (2022) Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol 13:866092","DOI":"10.3389\/fimmu.2022.866092"},{"key":"7402_CR60","doi-asserted-by":"publisher","first-page":"e200044","DOI":"10.1212\/NXI.0000000000200044","volume":"10","author":"M Rival","year":"2023","unstructured":"Rival M, Thouvenot E, Terdonck DTDL et al (2023) Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome. Neurol Neuroimmunol Neuroinflamm 10:e200044","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"7402_CR61","doi-asserted-by":"crossref","unstructured":"Schneider R, Brand-Arzamendi K, Reynold Lim T, Lee LE, Guenette M, Suthiphosuwan S, Bharatha A, Oh J (2024) Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome. Mult Scler 30(2):156\u2013165","DOI":"10.1177\/13524585231219131"},{"key":"7402_CR62","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1212\/WNL.0000000000207664","volume":"101","author":"A Cobo-Calvo","year":"2023","unstructured":"Cobo-Calvo A, Tur C, Otero-Romero S et al (2023) Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event. Neurology 101:e1280\u2013e1292","journal-title":"Neurology"},{"key":"7402_CR63","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.26555","volume":"93","author":"TD Okuda","year":"2023","unstructured":"Okuda TD, Kantarci O, Lebrun-Fr\u00e9nay C et al (2023) Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Ann Neurol 93:604\u2013614","journal-title":"Ann Neurol"},{"key":"7402_CR64","doi-asserted-by":"publisher","first-page":"104143","DOI":"10.1016\/j.msard.2022.104143","volume":"68","author":"EE Longbrake","year":"2022","unstructured":"Longbrake EE, Hua HL, Mowry ME et al (2022) The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders 68:104143","journal-title":"Multiple Sclerosis and Related Disorders"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07402-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T01:04:41Z","timestamp":1718327081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07402-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7402"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07402-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Jo\u00e3o Moura received support to attend scientific conferences\/meetings from Orphalan, Sanofi, Novartis, UCB, Alnylam and Alexion.Cristina Granziera\u2014The University Hospital Basel (USB) and the Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), as the employer of C.G., have received the following fees which were used exclusively for research support: (i) advisory boards and consultancy fees from Actelion, Novartis, Genzyme-Sanofi, GeNeuro, Hoffmann La Roche, Janssen, Merck, Biogen and Siemens; (ii) speaker fees from Biogen, Hoffmann La Roche, Teva, Novartis, Jannsen, Merck and Genzyme-Sanofi; (iii) research grants: Hoffmann La Roche, GeNeuro, Novartis, Genzyme-Sanofi and Biogen.M\u00f3nica Marta received support to attend scientific conferences\/meetings from Novartis and Merck.Ana Martins Silva has received compensation as a speaker in meetings and for consulting, clinical trial research, and advisory board participation from Biogen, Bayer, Merck Serono, Novartis, Roche, and Sanofi-Genzyme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}